Clinical trials: Neoplasms, Metastatic
Kidney Cancer, Renal Cell Carcinoma
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
To assess whether changes in quantitative tumor perfusion parameters after 3 or 6 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to…
- Conditions
- Kidney Cancer, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT04508725
- Testing
- Doppler Ultrasound, SIEMENS S3000 and Verasonics Vantage 256, Standard-of-care Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Oral Mucositis
Study of Dentoxol® Mouthrinse for Oral Mucositis
The primary objective of this study is to determine the efficacy of Dentoxol® mouthrinse in reducing the severity of oral mucositis secondary to radiation therapy for head and neck cancer.
- Trial name
- NCT02885376
- Testing
- Dentoxol
- Where
- 3 sites in Chile
- Volunteers
- 108 people
- Sponsor
- Ingalfarma SpA
Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
This phase I trial studies the side effects and best dose of olaparib when given with hyperthermia in treating patients with breast cancer that has come back in the chest wall.
- Trial name
- NCT03955640
- Testing
- Olaparib, Hyperthermia Treatment, Questionnaire Administration
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Thomas Jefferson University
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with erlotinib, and to assess the pharmacokinetics of CS-7017 in combination with…
- Trial name
- NCT01199068
- Testing
- CS-7017, Erlotinib
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Neoplasm Metastasis
Proteome-based Immunotherapy of Brain Metastases From Breast Cancer
Trial Hypothesis: Acute, progressing lethal neurooncological process can be transferred into chronic and non-lethal, the survival rates and life quality can be improved by of control of tumor cells (TCs) quantity and targeted…
- Trial name
- NCT01782274
- Testing
- Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes, Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- NeuroVita Clinic
Lymphedema, Lymphedema of Face
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and fibrosis (LEF) in head and neck cancer (HNC) survivors.
- Conditions
- Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation
- Trial name
- NCT04797390
- Testing
- Advanced Pneumatic Compression Device (APCD), Usual Care
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tactile Medical
Liver Cancer (Primary and Metastatic)
Short-term Embolization Using Gelatin Particles for FloW ModulAtion During Y90 Radioembolization
The SEGWAY trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of flow diversion to protect non-tumorous liver function using short-acting gelatin sponge particles during Yttrium-90…
- Trial name
- SEGWAY (NCT06229080)
- Testing
- NexGel
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Next Biomedical Co., Ltd.
Breast Neoplasms, Neoplasms by Site
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line Capecitabine plus Docetaxel chemotherapy in…
- Conditions
- Breast Neoplasms, Neoplasms by Site, Neoplasm Metastasis, Breast Diseases
- Trial name
- CAMELLIA (NCT01917279)
- Testing
- Docetaxel plus Capecitabine, Intermittent Capecitabine, Metronomic Capecitabine
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Binghe Xu
Colorectal Cancer
Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
The optimum regimen of maintenance treatment after first-line chemotherapy in patients with metastatic colorectal cancer (mCRC) is unknown.
- Trial name
- NCT02893540
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breastcancer
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers
Whole-body MRI including diffusion is a booming technique. Numerous studies have demonstrated its interest in metastatic cancers.
- Trial name
- NCT02966574
- Testing
- whole body MRI
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Brugmann University Hospital
Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor
Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors
This phase II trial studies how well a second curettage (removal of the abnormal cancer cells in the uterus using a method of surgically removing the lining of the uterus) works in treating patients with gestational trophoblastic…
- Conditions
- Complete Hydatidiform Mole, Non-Metastatic Gestational Trophoblastic Tumor, Partial Hydatidiform Mole
- Trial name
- NCT00521118
- Testing
- Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- 29 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Gynecologic Oncology Group
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Long-term Effects Secondary to Cancer Therapy in Adults
Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Longitudinal Trial
Population studies associate a higher intake of cruciferous vegetables with a reduced risk of cancer. Studies identified PEITC and several active isothiocyanates in watercress extract that may have significant anticarcinogenic…
- Trial name
- NCT02468882
- Testing
- Watercress
- Where
- Portugal
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Lisbon
Cancer
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
This is an open label, multicenter, non-comparative, phase IV study of panitumumab monotherapy in Indian subjects with previously treated, wild-type Kirsten rat sarcoma viral oncogene homolog (KRAS) and wild-type Neuroblastoma…
- Trial name
- NCT02301962
- Testing
- Panitumumab
- Where
- 12 sites in India
- Volunteers
- 58 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis
- Trial name
- THUNDER (NCT07152782)
- Testing
- Neratinib, Trastuzumab Deruxtecan
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Fudan University
Metastatic Lung Cancer
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible.
- Trial name
- LIBERTYLUNG (NCT04790682)
- Testing
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Institut Curie
Prostate Cancer
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a two-arm, randomized Phase II study of intermittent chemotherapy with and without GM-CSF. All patients will receive six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days…
- Trial name
- NCT00488982
- Testing
- Docetaxel, Docetaxel and GM-CSF
- Where
- 4 sites in United States
- Volunteers
- 125 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.